|
Gender (female)
|
18 (24%)
|
38 (25%)
|
*
|
|
Mean age (years)
|
44
|
46
|
*
|
|
Weight (kg)
|
70
|
72
|
*
|
|
Mechanism of transmission
|
*
|
|
Homosexual
|
18 (25%)
|
37 (25%)
|
*
|
|
IVDU
|
29 (39%)
|
52 (35%)
|
*
|
|
Heterosexual
|
19 (25%)
|
48 (32%)
|
*
|
|
Unknown
|
7 (9%)
|
12 (8%)
|
*
|
|
Concomitant pathologies
| |
*
|
|
AIDS
|
18 (24%)
|
46 (30%)
|
*
|
|
HCV
|
31 (40%)
|
56 (39%)
|
*
|
|
Psychiatric history
|
17 (23%)
|
27 (18%)
|
*
|
|
Methadone consumption
|
5 (6%)
|
22 (14%)
|
*
|
|
Use of psychopharmaceuticals
|
14 (19%)
|
19 (13%)
|
*
|
|
FDCs
| | |
*
|
|
AtriplaTM
|
36 (48%)
|
72 (48%)
|
*
|
|
TruvadaTM
|
24 (32%)
|
48 (32%)
|
*
|
|
KivexaTM
|
7 (9%)
|
16 (11%)
|
*
|
|
CombivirTM
|
6 (8%)
|
14 (9%)
|
*
|
|
TrizivirTM
|
2 (3%)
|
0 (0%)
|
*
|
|
NNRTI
|
15 (20%)
|
28 (19%)
|
*
|
|
PI
|
22 (29%)
|
54 (36%)
|
*
|
|
Integrase
|
0 (0%)
|
3 (2%)
|
*
|
|
Exposure time to FDCs (months)
|
27 (range: 1–121)
|
24 (range: 3–98)
|
*
|
|
Exposure time to efavirenz (months)
|
50 (range: 129–1)
|
61 (range: 126–3)
|
*
|
|
Viral load > 50 copies/mL at visit −1
|
12 of 74 (16.2%)
|
8 of 149 (5.4%)
|
(OR: 3.4; 95%CI: 1.3-8.8; p = 0.02)
|
|
Viral load > 50 copies/mL at baseline visit
|
10 of 74 (13.5%)
|
10 of 146 (6.8%)
|
*
|
|
CD4 at first visit (cells/μL)
|
573 (range: 41–1527)
|
542 (range: 92–1481)
|
*
|
